Blog

Brendon Stiles: We owe it to our patients with EGFR mutations

montefioreeinsteinnow.org

Oct 15, 2024, 12:59

Brendon Stiles: We owe it to our patients with EGFR mutations

Brendon Stiles, Professor and Chief, Thoracic Surgery and Surgical Oncology,

“There are some patients with EGFR mutations who respond to immunotherapy, particularly when combined with chemotherapy or anti-angiogenesis drugs. We owe it to our patients with EGFR mutations to figure out who benefits from these strategies.”

Quoting The Lancet Oncology:

“ICYMI:
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated tumors non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis.”

Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis

Authors: Yi Zhao, Ying He, Wei Wang, Qi Cai, Fan Ge, Zisheng Chen, Jianqi Zheng, Yuan Zhang, Hongsheng Deng, Ying Chen, Shen Lao, Hengrui Liang, Prof Wenhua Liang, MDa, Prof Jianxing He.

Brendon Stiles: We owe it to our patients with EGFR mutations

anti-angiogenesis drugs Brendon Stiles cancer Cancer research chemotherapy EGFR Mutations Fan Ge Hengrui Liang Hongsheng Deng immunotherapy Jianqi Zheng Jianxing He Montefiore Health System non small cell lung cancer OncoDaily Oncology Qi Cai Shen Lao The Lancet Oncology Wei Wang Wenhua Liang Yi Zhao Ying Chen Ying He Yuan Zhang Zisheng Chen

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer